

## **Paul Hermes Joins Biorez Board of Directors**

*Veteran Medical Device Executive Joins Regenerative Medicine Company as it Aims to Replace Autografts and Allografts with its Bioresorbable Scaffold Technology*

New Haven, CT ([PRWEB](#)) September 21, 2017 -- [Biorez, Inc.](#), a regenerative medicine company developing bioresorbable scaffold technology, today announced the election of Paul Hermes, Entrepreneur in Residence at Medtronic, Inc., to serve as an Independent Director on its Board of Directors.

Biorez has developed a proprietary, tissue-engineered scaffold for anterior cruciate ligament (ACL) reconstruction that is designed to stabilize the knee and facilitate regeneration of the ACL. The Biorez ACL implant is the first clinical application of its platform resorbable scaffold technology. The company is currently conducting preclinical studies and expects results in 2018.

“We are extremely pleased to announce the addition of Paul Hermes to our Board,” said Kevin Rocco, Biorez CEO. “Paul is a seasoned medical device executive with a strong history of commercializing new medical technologies. We expect that his experience, counsel, and leadership will be a great benefit to our team.”

Hermes will join existing board members Konstantine Drakonakis, Launch Capital; Richard Emmitt, The Vertical Group; Kevin Rocco, Biorez; and Dan Wagner, Connecticut Innovations. Hermes is currently Medtronic’s Entrepreneur in Residence responsible for the incubation of technologies to revolutionize the practice of surgery. He previously served as Chief Technology Officer, Vice President, Research and Development for Covidien’s Surgical Solutions segment. His teams have launched some of the medical device industry’s benchmark products, including the TriStaple™, iDrive™, SILS™, AbsorbaTack™ and LigaSure™ product lines.

Hermes added, “It is an exciting time to join Biorez as the company is conducting preclinical testing and preparing for human trials.”

Biorez’s product can be described as a synthetic ACL that incorporates into the body similar to autograft and allograft. Rocco further explained, “When a tissue graft is implanted into the body a lot of regenerative work happens, cells infiltrate the graft, new blood vessels form, and cells work to remodel structural proteins to meet the demands of the new environment. We have developed a synthetic graft that harnesses this process.”

Hermes is the holder of a number of US and international patents. He currently serves as the Chairman of the Board of Directors of the Connecticut Technology Council. He serves on the Advisory Board for the University of New Haven School of Arts and Sciences. He is a member of the Board of Directors at MindUP, the Digital Health Incubator, where he advises a number of startups and accelerators. Hermes has been honored with the highest technical honors of Covidien and Medtronic, the 2014 Covidien Chairman’s Lifetime Innovator Award and a 2015 induction into the Medtronic Bakken Society.

About Biorez, Inc.

Biorez, Inc. is a privately held early-stage regenerative medicine company engaged in developing bioresorbable scaffold implants to reconstruct and regenerate functional tissue in vivo. Its lead product candidate is an off-the-shelf implant for ACL reconstruction that spares harvesting of patient donor-tissue, and provides a better



alternative to cadaver-based allograft. The company plans to commercialize its lead ACL technology, as well as expand its platform to new and innovative clinical applications. To learn more, visit [www.biorez.com](http://www.biorez.com).



**Contact Information**

**Monica L. Katzen**

Biorez

<http://biorez.com/>

+1 860.916.3442

**Online Web 2.0 Version**

You can read the online version of this press release [here](#).